Pelthos Therapeutics Inc. Debt Conversion, Converted Instrument, Amount
Pelthos Therapeutics Inc. (PTHS) reported Debt Conversion, Converted Instrument, Amount of $0 for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Financing Activities
us-gaap:DebtConversionConvertedInstrumentAmount1 · last filed 2026-08-13
- Pelthos Therapeutics Inc. debt conversion, converted instrument, amount for fiscal 2025 was $737.00K, a 45.93% decline from fiscal 2024.
- Pelthos Therapeutics Inc. debt conversion, converted instrument, amount for fiscal 2024 was $1.36M.
| Period end | Debt Conversion, Converted Instrument, Amount 6 month | Debt Conversion, Converted Instrument, Amount 12 month |
|---|---|---|
| 2026-06-30 | $0.00 10-Q · filed 2026-08-13 | |
| 2025-12-31 | $737.00K 10-K · filed 2026-03-19 | |
| 2025-06-30 | $737.00K 10-Q · filed 2026-08-13 | |
| 2024-12-31 | $1.36M 10-K · filed 2026-03-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |